Abstract:

Menopausal hormone therapy (MHT) is an effective treatment for alleviating menopausal syndrome, and 18.16% of perimenopausal women are receiving MHT treatment at present. Most gynecological malignancies are hormone-dependent, so the safety and efficacy of MHT in women with menopausal syndrome and those women with gynecological malignancies combined with menopausal syndrome are still controversial. For the menopausal syndrome patients without gynecological malignancies, reasonable selection of estrogen therapy may reduce the risk of ovarian cancer, and selection of MHT containing progesterone may reduce the risk of endometrial cancer and cervical cancer. As for epithelial ovarian cancer, early endometrial cancer, cervical squamous cell carcinoma, vaginal squamous cell carcinoma and vulvar squamous cell carcinoma, reasonable selection of MHT regimen may not increase the risk of recurrence, while may prolong the survival. By reviewing the MHT guidelines and the related clinical studies issued globally in recent years, we discuss how to rationally select MHT regimens to reduce the risk of gynecological malignancies in women with menopausal syndrome, how to reduce the recurrence risk of patients with gynecological malignancies combined with menopausal syndrome, and how to improve the survival rate of patients with gynecological malignant tumors.

Key words: Genital neoplasms, female, Estrogen replacement therapy, Recurrence, Survival rate, Therapy